5 Key Takeaways

• 1

  Sustained-release intracameral implants significantly improve patients' quality of life while minimizing clinic disruption.

• 2

  Durysta and iDose TR are FDA-approved implants that provide targeted medication delivery for open-angle glaucoma and ocular hypertension.

• 3

  Both implants reduce the burden of topical medications, addressing issues like non-adherence and side effects.

• 4

  Efficient implantation and streamlined postoperative care enhance clinic workflow and patient management.

• 5

  Collaboration with drug manufacturers' billing specialists can alleviate administrative burdens in ophthalmology practices.